SARS-CoV-2 antibody levels and long COVID occurrence in blood donors.
COVID‐19
COVID‐19 serological testing
blood donors
post‐acute COVID‐19 syndrome
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
revised:
21
06
2024
received:
22
04
2024
accepted:
23
06
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
Long COVID is a common condition lacking consensus definition; determinants remain incompletely understood. Characterizing immune profiles associated with long COVID could support the development of preventive and therapeutic strategies. We used a survey to investigate blood donors' infection/vaccination history and acute/persistent symptoms following COVID-19. The prevalence of long COVID was evaluated using self-report and an adapted definition from the RECOVER study. We evaluated factors associated with long COVID, focusing on anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies. Lastly, we investigated long COVID clinical subphenotypes using hierarchical clustering. Of 33,610 participants, 16,003 (48%) reported having had COVID-19; 1853 (12%) had self-reported long COVID, 685 (4%) met an adapted RECOVER definition, and 2050 (13%) met at least one definition. Higher anti-nucleocapsid levels measured 12-24 weeks post-infection were associated with higher risk of self-reported and RECOVER long COVID. Higher anti-spike IgG levels measured 12-24 weeks post-infection were associated with lower risk of self-reported long COVID. Higher total anti-spike measured 24-48 weeks post-infection was associated with lower risk of RECOVER long COVID. Cluster analysis identified four clinical subphenotypes; patterns included neurological and psychiatric for cluster 1; neurological and respiratory for cluster 2; multi-systemic for cluster 3; and neurological for cluster 4. Long COVID prevalence in blood donors varies depending on the adopted definition. Anti-SARS-CoV-2 antibodies were time-dependently associated with long COVID; higher anti-nucleocapsid levels were associated with higher risk; and higher anti-spike levels were associated with lower risk of long COVID. Different underlying pathophysiologic mechanisms may be associated with distinct clinical subphenotypes.
Sections du résumé
BACKGROUND
BACKGROUND
Long COVID is a common condition lacking consensus definition; determinants remain incompletely understood. Characterizing immune profiles associated with long COVID could support the development of preventive and therapeutic strategies.
METHODS
METHODS
We used a survey to investigate blood donors' infection/vaccination history and acute/persistent symptoms following COVID-19. The prevalence of long COVID was evaluated using self-report and an adapted definition from the RECOVER study. We evaluated factors associated with long COVID, focusing on anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies. Lastly, we investigated long COVID clinical subphenotypes using hierarchical clustering.
RESULTS
RESULTS
Of 33,610 participants, 16,003 (48%) reported having had COVID-19; 1853 (12%) had self-reported long COVID, 685 (4%) met an adapted RECOVER definition, and 2050 (13%) met at least one definition. Higher anti-nucleocapsid levels measured 12-24 weeks post-infection were associated with higher risk of self-reported and RECOVER long COVID. Higher anti-spike IgG levels measured 12-24 weeks post-infection were associated with lower risk of self-reported long COVID. Higher total anti-spike measured 24-48 weeks post-infection was associated with lower risk of RECOVER long COVID. Cluster analysis identified four clinical subphenotypes; patterns included neurological and psychiatric for cluster 1; neurological and respiratory for cluster 2; multi-systemic for cluster 3; and neurological for cluster 4.
DISCUSSION
CONCLUSIONS
Long COVID prevalence in blood donors varies depending on the adopted definition. Anti-SARS-CoV-2 antibodies were time-dependently associated with long COVID; higher anti-nucleocapsid levels were associated with higher risk; and higher anti-spike levels were associated with lower risk of long COVID. Different underlying pathophysiologic mechanisms may be associated with distinct clinical subphenotypes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CDC HHS
ID : 75D30120C08170
Pays : United States
Informations de copyright
© 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146.
Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS‐CoV‐2 infection. JAMA. 2023;329(22):1934–1946.
Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)‐a systematic review and meta‐analysis. J Med Virol. 2022;94(1):253–262.
Cutler DM. The costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809.
Arjun MC, Singh AK, Pal D, Das K, Alekhya G, Venkateshan M, et al. Characteristics and predictors of long COVID among diagnosed cases of COVID‐19. PLoS One. 2022;17(12):e0278825.
Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631.
Barnkob MB, Pottegård A, Støvring H, Haunstrup TM, Homburg K, Larsen R, et al. Reduced prevalence of SARS‐CoV‐2 infection in ABO blood group O. Blood Adv. 2020;4(20):4990–4993.
Al‐Youha SA, Alduaij W, Al‐Serri A, Almazeedi SM, Al‐Haddad M, Jamal MH, et al. The impact of ABO blood groups on clinical outcomes and susceptibility to COVID ‐19: a retrospective study in an unselected population. Transfusion. 2021;61(5):1631–1641.
Abuawwad MT, Taha MJJ, Abu‐Ismail L, Alrubasy WA, Sameer SK, Abuawwad IT, et al. Effects of ABO blood groups and RH‐factor on COVID‐19 transmission, course and outcome: a review. Front Med. 2023;12(9):1045060.
Moslemi C, Sækmose S, Larsen R, Brodersen T, Didriksen M, Hjalgrim H, et al. A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID‐19 susceptibility, severity, and long COVID‐19. Transfusion. 2023;63(1):47–58.
Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. Long‐term SARS‐CoV‐2‐specific immune and inflammatory responses in individuals recovering from COVID‐19 with and without post‐acute symptoms. Cell Rep. 2021;36(6):109518.
Chen B, Julg B, Mohandas S, Bradfute SB. RECOVER mechanistic pathways task force. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;4(12):e86015.
Jia X, Cao S, Lee AS, Manohar M, Sindher SB, Ahuja N, et al. Anti‐nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post–COVID‐19 syndrome. JCI Insight. 2022;7(13):e156713.
Varnai R, Molnar T, Zavori L, Tőkés‐Füzesi M, Illes Z, Kanizsai A, et al. Serum level of anti‐nucleocapsid, but not anti‐spike antibody, is associated with improvement of long COVID symptoms. Vaccine. 2022;10(2):165.
García‐Abellán J, Padilla S, Fernández‐González M, García JA, Agulló V, Andreo M, et al. Antibody response to SARS‐CoV‐2 is associated with Long‐term clinical outcome in patients with COVID‐19: a longitudinal study. J Clin Immunol. 2021;41(7):1490–1501.
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post‐COVID syndrome in non‐hospitalised patients with COVID‐19: a longitudinal prospective cohort study. Lancet Region Health. 2021;6:100122.
Hsu FC, Pan LC, Huang YF, Yang CH, Shiu MN, Lin HJ. A dynamic model for estimating the retention duration of neutralizing antibody titers after vaccination in a COVID‐19 convalescent population. J Infect Dis. 2024;229(2):398–402. https://doi.org/10.1093/infdis/jiad431
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS‐CoV‐2 infection in humans. Nat Microbiol. 2020;5(12):1598–1607.
Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389–398.
Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. Data‐driven identification of post‐acute SARS‐CoV‐2 infection subphenotypes. Nat Med. 2023;29(1):226–235.
Kenny G, McCann K, O'Brien C, Savinelli S, Tinago W, Yousif O, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self‐reported symptoms. Open Forum Infect Dis. 2022;9(4):ofac060.
Gentilotti E, Górska A, Tami A, Gusinow R, Mirandola M, Rodríguez Baño J, et al. Clinical phenotypes and quality of life to define post‐COVID‐19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. eClinicalMedicine. 2023;62:102107.
Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, et al. Large‐scale phenotyping of patients with long COVID post‐hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25(4):607–621.
Busch MP, Stramer SL, Stone M, Yu EA, Grebe E, Notari E, et al. Population‐weighted seroprevalence from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, vaccination, and hybrid immunity among US blood donations from January to December 2021. Clinic Infect Dis. 2022;75(Supplement_2):S254–S263.
Jones JM, Opsomer JD, Stone M, Benoit T, Ferg RA, Stramer SL, et al. Updated US infection‐ and vaccine‐induced SARS‐CoV‐2 seroprevalence estimates based on blood donations, July 2020‐December 2021. JAMA. 2022;328(3):298–301.
Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US infection‐ and vaccine‐induced SARS‐CoV‐2 seroprevalence based on blood donations, July 2020‐May 2021. JAMA. 2021;326(14):1400–1409.
Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573.
Shah MM, Spencer BR, James‐Gist J, Haynes JM, Feldstein LR, Stramer SL, et al. Long‐term symptoms associated with SARS‐CoV‐2 infection among blood donors. JAMA Netw Open. 2024;7(4):e245611.
Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID‐19: a systematic review. Int J Clin Pract. 2021;75(10):e14357.
Centers for Disease Control and Prevention. Long COVID or Post‐COVID conditions. [Internet]. [cited 2023 Dec 14]. Available from: https://www.cdc.gov/coronavirus/2019‐ncov/long‐term‐effects/index.html#:~:text=Long%20COVID%20is%20broadly%20defined,after%20acute%20COVID%2D19%20infection
Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139–148.
Files JK, Sarkar S, Fram TR, Boppana S, Sterrett S, Qin K, et al. Duration of post‐COVID‐19 symptoms are associated with sustained SARS‐CoV‐2 specific immune responses. JCI Insight [Internet]. 2021 Jun 18 [cited 2023 Dec 14]; Available from: http://insight.jci.org/articles/view/151544
Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, et al. Persistent symptoms after COVID‐19 are not associated with differential SARS‐CoV‐2 antibody or T cell immunity. Nat Commun. 2023;14(1):5139.
Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID‐19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191–1198.
Pereira C, Harris BHL, Di Giovannantonio M, Rosadas C, Short CE, Quinlan R, et al. The association between antibody response to severe acute respiratory syndrome coronavirus 2 infection and Post‐COVID‐19 syndrome in healthcare workers. J Infect Dis. 2021;223(10):1671–1676.
Imai K, Kitagawa Y, Tabata S, Kubota K, Nagura‐Ikeda M, Matsuoka M, et al. Antibody response patterns in COVID‐19 patients with different levels of disease severity in Japan. J Med Virol. 2021;93(5):3211–3218.
Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, et al. Anti‐SARS‐CoV‐2 IgG levels in relation to disease severity of COVID‐19. J Med Virol. 2022;94(1):380–383.
Kallaste A, Kisand K, Aart A, Kisand K, Peterson P, Lember M. Antibody levels remain high to one‐year's follow‐up after moderate and severe COVID‐19, but not after mild cases. Infect Dis. 2022;54(5):345–355.
Plūme J, Galvanovskis A, Šmite S, Romanchikova N, Zayakin P, Linē A. Early and strong antibody responses to SARS‐CoV‐2 predict disease severity in COVID‐19 patients. J Transl Med. 2022;20(1):176.
Bläckberg A, Fernström N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID‐19 a prospective observational study. PLoS One. 2021;16(3):e0248918.
Stich M, Benning L, Speer C, Garbade SF, Bartenschlager M, Kim H, et al. Waning immunity 14 months after SARS‐CoV‐2 infection. Pediatrics. 2022;150(5):e2022057151.
Ishizaki A, Bi X, Nguyen QT, Maeno T, Hara A, Nakamura H, et al. Neutralizing‐antibody response to SARS‐CoV‐2 for 12 months after the COVID‐19 workplace outbreaks in Japan. PLoS One. 2022;17(8):e0273712.
Montesinos I, Dahma H, Wolff F, Dauby N, Delaunoy S, Wuyts M, et al. Neutralizing antibody responses following natural SARS‐CoV‐2 infection: dynamics and correlation with commercial serologic tests. J Clin Virol. 2021;144:104988.
Garcia‐Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID‐19‐neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–488.e11.
Tsuchida T, Yoshimura N, Ishizuka K, Katayama K, Inoue Y, Hirose M, et al. Five cluster classifications of long COVID and their background factors: a cross‐sectional study in Japan. Clin Exp Med. 2023;23(7):3663–3670.
Fischer A, Badier N, Zhang L, Elbéji A, Wilmes P, Oustric P, et al. Long COVID classification: findings from a clustering analysis in the Predi‐COVID cohort study. Int J Environ Res Public Health. 2022;19(23):16018.
Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413.
Fink RV, Fisher L, Sulaeman H, Dave H, Levy ME, McCann L, et al. How do we …form and coordinate a national serosurvey of SARS‐CoV‐2 within the blood collection industry? Transfusion. 2022;62(7):1321–1333.